The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Growing evidence suggests that elevated cholesterol levels in mid‐life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily). Methods: This is an international, multicenter, double‐blind, randomized, parallel‐group study with a double‐blind randomized withdrawal phase of patients with mild to moderate AD (Mini‐Mental State Examination [MMSE] score, 13 to 25). Inclusion criteria included age 50 to 90 years, receiving donepezil 10 mg for at least 3 months before randomization, and low‐density lipoprotein cholesterol levels (LDL‐C) 2.5 to 3.5 mmol/L (95 to 195 mg/dL). Co‐primary end points are changes in AD Assessment Scale‐cognitive subscale (ADAS‐cog) and AD Cooperative Study‐Clinical Global Impression of Change (ADCS‐CGIC) scale scores. A confirmatory end point is rate of change in whole brain and hippocampal volumes in patients who enrolled in the magnetic resonance imaging substudy. Results: Enrollment of 641 subjects is complete. The baseline mean data are age 74 ± 8 years, 53% women, MMSE 22 ± 3, ADAS‐cog 23 ± 10, AD Functional Assessment and Change Scale (ADFACS) 13 ± 9, Neuropsychiatric Inventory (NPI) 10 ± 11, and Clinical Dementia Rating‐Sum of Boxes (CDR‐SB) 6 ± 3. Mean prior donepezil treatment was 409 ± 407 days. Mean baseline lipid levels are total cholesterol 5.8 ± 0.8 mmol/L (224 ± 33 mg/dL), LDL‐C 3.7 ± 0.7 mmol/L (143 ± 26 mg/dL), triglycerides 1.5 ± 0.7 mmol/L (132 ± 64 mg/dL), and high‐density lipoprotein cholesterol 1.6 ± 0.5 mmol/L (64 ± 18 mg/dL). Conclusions: LEADe will report in 2008 and is expected to provide a more definitive evaluation of the potential for statins in the treatment of people with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationShepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Helkala, E.-L., Tuomilehto, J., Soininen, H., & Nissinen, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1556 · Cited by 1,291 · cited 2×
“[2] Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, et al.”
BackgroundSelf-citationMidlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Research works printed but not linked: 45
- 10.2105/AJPH.88.9.1337 · DOI · Paper page
- 10.1177/089198879600900201 · DOI
- 10.1001/archneur.59.3.378 · DOI · Paper page
- 10.1212/WNL.57.8.1447 · DOI · Paper page
- 10.1212/01.WNL.0000070182.02537.84 · DOI · Paper page
- 10.1016/0197-4580(90)90024-T · DOI · Paper page
- 10.1016/S0197-4580(00)83093-6 · doi:10.1016/s0197-4580(00)83093-6
- 10.1111/j.1600-0404.2006.00687.x · DOI · Paper page
- 10.1126/science.8346443 · DOI · Paper page
- 10.1016/S0140-6736(00)03155-X · DOI · Paper page
- 10.1001/archneur.59.2.223 · DOI · Paper page
- 10.1001/archneur.57.10.1439 · DOI · Paper page
- 10.1186/1741-7015-5-20 · DOI · Paper page
- 10.1212/01.WNL.0000142963.90204.58 · DOI · Paper page
- 10.1001/archneur.62.7.1047 · DOI · Paper page
- ZArvanitakis JASchneider RSWilson JLBienias JFKelly DAEvans et al.Statins incident Alzheimer disease change in cognitive function and neuropathology. Neurology (in press).
- 10.1016/S0140-6736(02)09327-3 · DOI · Paper page
- 10.1016/S0140-6736(05)67394-1 · DOI · Paper page
- 10.1073/pnas.081620098 · DOI · Paper page
- 10.1073/pnas.95.11.6460 · DOI · Paper page
- 10.1002/ana.10292 · DOI · Paper page
- 10.1159/000084550 · DOI · Paper page
- 10.1159/000069989 · DOI · Paper page
- 10.1001/archneur.62.5.753 · DOI · Paper page
- 10.1111/j.1600-0404.2006.00688.x · DOI · Paper page
- 10.1097/00001756-200109170-00036 · DOI
- 10.1111/j.1600-0404.2006.00690.x · DOI · Paper page
- 10.1111/j.1600-0404.2006.00684.x · DOI · Paper page
- 10.1161/01.CIR.0000091404.09558.AF · DOI · Paper page
- 10.1161/01.CIR.103.1.113 · DOI · Paper page
- 10.1161/hc2401.092816 · DOI · Paper page
- American Psychiatric Association, 1987, Diagnostic and statistical manual of mental disorders
- 10.1212/WNL.34.7.939 · DOI · Paper page
- 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- 10.1016/j.ahj.2004.07.025 · DOI
- 10.1016/j.amjopharm.2006.06.001 · DOI
- 10.1212/WNL.57.3.481 · DOI · Paper page
- 10.1212/WNL.57.3.489 · DOI · Paper page
- 10.1176/ajp.141.11.1356 · DOI · Paper page
- 10.1097/00002093-199700112-00004 · DOI · Paper page
- 10.1212/WNL.50.1.136 · DOI · Paper page
- 10.1159/000091790 · DOI · Paper page
- 10.1001/archinte.158.9.1021 · DOI · Paper page
- 10.1212/01.wnl.0000256368.57375.b7 · DOI · Paper page
- 10.1001/archneur.64.1.103 · DOI · Paper page
Cited by
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261
Self-citationStatins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Self-citation
Metadata
- Authors
- Jones, R. W., Kivipelto, M., Feldman, H., Sparks, L., Doody, R., Waters, D. D., Hey-Hadavi, J., Breazna, A., Schindler, R. J., Ramos, H., & LEADe investigators
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2008-03
- Volume
- 4
- Issue
- 2
- Pages
- 145-153
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2010754109
- Cited by
- 71
- References
- 7
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Pfizer
- Eisai
- Novartis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. https://app.cochat.ai/papers/10.1016/j.jalz.2008.02.001
- The paper
- Jones, R. W., Kivipelto, M., Feldman, H., Sparks, L., Doody, R., Waters, D. D., Hey-Hadavi, J., Breazna, A., Schindler, R. J., Ramos, H., & LEADe investigators. (2008). The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2008.02.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.